RE: Phase 1, 2, 3... 4 (post market monitoring)4 Sep 2025 14:07
Would love that to be the case d200 but there is no chance. The company are full of hype and that interview was, imo, misleading. They need to be more specific instead of making reckless and ambiguous comments that lead people to think some wonderful drug is hitting the market soon.